Reavey-Cantwell John F, Fox W Christopher, Reichwage Brett D, Fautheree Gregory L, Velat Gregory J, Whiting Jobyna H, Chi Yueh-Yun, Hoh Brian L
Department of Neurological Surgery, University of Florida, Gainesville, Florida 32610-0265, USA.
Neurosurgery. 2009 May;64(5):890-5; discussion 895-6. doi: 10.1227/01.NEU.0000341904.39691.2F.
Antiplatelet therapy is critical to endovascular neurosurgical procedures. Some patients are aspirin-resistant nonresponders. We reviewed our endovascular neurosurgery patients who were premedicated with aspirin and clopidogrel and identified nonresponders to aspirin. Factors associated with aspirin resistance were determined.
Consecutive endovascular neurosurgery patients were identified who were treated by the senior author (BLH) from December 2006 to October 2007 and who were premedicated with aspirin (325 mg) and clopidogrel (75 mg) for 7 days before the procedure. We retrospectively reviewed values from the platelet function analyzer-100 test (Dade-Behring, Deerfield, IL) from 1 day before the procedures. The following factors were evaluated for association with aspirin drug resistance: age, sex, body mass index, and smoking history; patients with hypertension, diabetes, coronary artery disease/ peripheral vascular disease, or hypercholesterolemia; disease pathology (aneurysm, intracranial stenosis, or extracranial stenosis); patients taking statins, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, or antidepressants; and white blood cell count, hemoglobin, hematocrit, and platelet levels. A stepwise logistic model selection was used to select important factors and their interactions.
Eighty-one consecutive patients with the following interventions were included in the study: 35 aneurysm coilings (43%), 21 stent-assisted aneurysm coilings (26%), 13 carotid stent and angioplasties (16%), 7 intracranial stents and angioplasties (9%), and 5 extracranial vertebral artery stents and angioplasties (6%). Seventeen patients (21%) were nonresponders to aspirin. After model selection, the only factor associated with aspirin resistance was not taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (P = 0.0348; odds ratio, 0.214; 95% confidence interval, 0.051-0.896).
Twenty-one percent of patients premedicated with aspirin and clopidogrel dual therapy for 7 days before endovascular neurosurgical procedures were nonresponders to aspirin. Patients not taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker may be at higher risk for aspirin drug resistance.
抗血小板治疗对于血管内神经外科手术至关重要。一些患者是阿司匹林抵抗无反应者。我们回顾了接受阿司匹林和氯吡格雷预处理的血管内神经外科手术患者,并确定了阿司匹林无反应者。确定了与阿司匹林抵抗相关的因素。
纳入2006年12月至2007年10月由资深作者(BLH)治疗的连续血管内神经外科手术患者,这些患者在手术前7天接受阿司匹林(325毫克)和氯吡格雷(75毫克)预处理。我们回顾性分析了手术前1天血小板功能分析仪-100测试(Dade-Behring,伊利诺伊州迪尔菲尔德)的值。评估以下因素与阿司匹林耐药性的相关性:年龄、性别、体重指数和吸烟史;患有高血压、糖尿病、冠状动脉疾病/外周血管疾病或高胆固醇血症的患者;疾病病理(动脉瘤、颅内狭窄或颅外狭窄);服用他汀类药物、β受体阻滞剂、血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂或抗抑郁药的患者;以及白细胞计数、血红蛋白、血细胞比容和血小板水平。采用逐步逻辑模型选择来选择重要因素及其相互作用。
该研究纳入了81例接受以下干预措施的连续患者:35例动脉瘤栓塞术(43%)、21例支架辅助动脉瘤栓塞术(26%)、13例颈动脉支架置入和血管成形术(16%)、7例颅内支架置入和血管成形术(9%)以及5例颅外椎动脉支架置入和血管成形术(6%)。17例患者(21%)对阿司匹林无反应。模型选择后,与阿司匹林抵抗相关的唯一因素是未服用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂(P = 0.0348;比值比,0.214;95%置信区间,0.051 - 0.896)。
在血管内神经外科手术前接受阿司匹林和氯吡格雷双重治疗7天的患者中,21%对阿司匹林无反应。未服用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的患者可能有更高的阿司匹林耐药风险。